Screening for Conditions by Electronic Nose Technology (SCENT III) (Clinical Trial Not Allowed)

forecasted

This NOFO seeks to develop electronic nose technologies that mimic the olfactory system, leading to a robust diagnostic platform subject to validation and regulatory approval. A previous iteration demonstrated the feasibility of developing safe and effective biosensing technologies for volatile organic compound (VOC) signatures from human skin through systems engineering and artificial intelligence. VOCs are biomarkers that underlie the effects of a wide array of diseases. Under this iteration of the NOFO, improved sensing, detection, and analytical technologies will be developed for integration into tools for disease diagnosis and monitoring in everyday settings. These novel technologies will complement traditional blood analysis and other invasive, expensive, and highly technical procedures to monitor the onset, progression, and resolution of disease. NCATS’ vision is to bring more treatments for all people more quickly. The electronic nose platform is noninvasive and makes diagnosis in real time, in situ. This NOFO seeks to improve the translation of existing knowledge for the prevention and treatment of various diseases conditions. Grant authorities that allow the National Center for Advancing Translational Science (NCATS) to forecast this opportunity are as follows: 42 U.S. Code § 287a - Cures Acceleration Network.